FDA accepts application for Roche’s Gazyva/Gazyvaro for the treatment of the most common form of lupus
F. Hoffmann-La Roche Ltd Filing acceptance based on phase III ALLEGORY data for Gazyva/Gazyvaro showing a significant reduction…
New England Journal of Medicine publishes phase III ALLEGORY data showing Roche’s Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus
Over three quarters of people on Gazyva/Gazyvaro plus standard therapy achieved at least a four-point improvement in SRI-4,…
Roche’s Gazyva Meets Phase III SLE Endpoints at 52 Weeks
Roche (RHHBY) announced on 3 November 2025 that the phase III ALLEGORY study…